All In MedTech

FDA Clearance Tracker · P200018

NeuRX Diaphragm Pacing System (DPS)

Premarket approval (PMA) is the pathway for the highest-risk devices. FDA reviews clinical evidence of safety and effectiveness before approving.

Last checked: Nov 20, 2026Latest source record: Mar 31, 2023 (this decision)Source: openFDAMethods & limitations

PMAFirst of its product code

Decided

Mar 31, 2023

Approved

Time to decision

1,114 days

Received Mar 12, 2020. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA

Device class

Class III

The decision

FDA number
P200018
Device name
NeuRX Diaphragm Pacing System (DPS)
Applicant location
Oberline, OH
Received
Mar 12, 2020
Decided
Mar 31, 2023
Decision
Approved

Device type

Device class
Class III

Every decision under product code OIR

FDA's approval statement

As written in FDA's record.

Approval for the NeuRx DPS® is intended for use in patients with stable, high spinal cord injuries with stimulatable diaphragms, but who lack control of their diaphragms. The device is indicated to allow the patients to breathe without the assistance of a mechanical ventilator for at least 4 continuous hours a day. For use only in patients 18 years of age or older.

How new is this?

These are facts about FDA's records. They are not a judgment about the device.

  • This is the earliest decision in FDA's data under product code OIR (diaphragmatic/phrenic nerve laparoscopically-implanted stimulator).
  • It is not on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026). FDA does not publish which devices hold the designation before they are authorized, and the list is updated only a few times a year.

Source documents

Other decisions for Synapse Biomedical, Inc.

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.